UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 47

Sortiert nach

A phase Ib/II study of xentuzumab, an IGF-neutralising antibody, combined with exemestane and everolimus in hormone receptor-positive, HER2-negative locally advanced/metastatic breast cancer

Breast cancer research : BCR, 2021-01, Vol.23 (1), p.8-8, Article 8

2021

Volltextzugriff (PDF)

Aurora kinases in ovarian cancer

ESMO open, 2020-10, Vol.5 (5), p.e000718-e000718, Article e000718

2020

Volltextzugriff (PDF)

MYC and MCL1 Cooperatively Promote Chemotherapy-Resistant Breast Cancer Stem Cells via Regulation of Mitochondrial Oxidative Phosphorylation

Cell metabolism, 2017-10, Vol.26 (4), p.633-647.e7

2017

Volltextzugriff (PDF)

Molecular biology in breast cancer: Intrinsic subtypes and signaling pathways

Cancer treatment reviews, 2012-10, Vol.38 (6), p.698-707

2012

Volltextzugriff (PDF)

Immunotherapies in ovarian cancer

European journal of cancer supplements, 2020-08, Vol.15, p.87-95

2020

Volltextzugriff (PDF)

Treatment of cervical cancer: the importance of a multidisciplinary team approach

Clinical & translational oncology, 2011-07, Vol.13 (7), p.431-433

2011

Volltextzugriff (PDF)

ER + Breast Cancers Resistant to Prolonged Neoadjuvant Letrozole Exhibit an E2F4 Transcriptional Program Sensitive to CDK4/6 Inhibitors

Clinical cancer research, 2018-06, Vol.24 (11), p.2517-2529

2018

Volltextzugriff (PDF)

Clinical implications of routine genomic mutation sequencing in PIK3CA/AKT1 and KRAS/NRAS/BRAF in metastatic breast cancer

Breast cancer research and treatment, 2016-11, Vol.160 (1), p.69-77

2016

Volltextzugriff (PDF)

Systemic treatment of newly diagnosed advanced epithelial ovarian cancer: From chemotherapy to precision medicine

Critical reviews in oncology/hematology, 2021-02, Vol.158, p.103209-103209, Article 103209

2021

Volltextzugriff (PDF)

EGF-Induced Acetylation of Heterogeneous Nuclear Ribonucleoproteins Is Dependent on KRAS Mutational Status in Colorectal Cancer Cells

PloS one, 2015-06, Vol.10 (6), p.e0130543-e0130543

2015

Volltextzugriff (PDF)

Cell proliferation inhibitors and apoptosis promoters

European journal of cancer supplements, 2020-08, Vol.15, p.73-76

Perez-Fidalgo, J. Alejandro

2020

Volltextzugriff (PDF)

Primary paraesophageal Ewing's sarcoma: an uncommon case report and literature review

OncoTargets and therapy, 2015-01, Vol.8 (default), p.1053-1059

2015

Volltextzugriff (PDF)

GEICO1601-ROLANDO: a multicentric single arm Phase II clinical trial to evaluate the combination of olaparib and pegylated liposomal doxorubicin for platinum-resistant ovarian cancer

Future science OA, 2019-02, Vol.5 (2), p.FSO370-FSO370

2019

Volltextzugriff (PDF)

Endometriosis-associated ovarian carcinomas: insights into pathogenesis, diagnostics, and therapeutic targets-a narrative review

Annals of translational medicine, 2020-12, Vol.8 (24), p.1712-1712

2020

Volltextzugriff (PDF)

2022-RA-459-ESGO UPLIFT (ENGOT-ov67/GOG-3048) a registrational trial of Upifitamab Rilsodotin (XMT-1536; UpRi), a NaPi2b-directed antibody drug conjugate (ADC) in platinum-resistant ovarian cancer

International journal of gynecological cancer, 2022-10, Vol.32 (Suppl 2), p.A237-A237

2022

Volltextzugriff (PDF)

Correction: ER + Breast Cancers Resistant to Prolonged Neoadjuvant Letrozole Exhibit an E2F4 Transcriptional Program Sensitive to CDK4/6 Inhibitors

Clinical cancer research, 2019-02, Vol.25 (4), p.1431-1431

2019

Volltextzugriff (PDF)

MYC and MCL1 cooperatively promote chemotherapy-resistant breast cancer stem cells through regulation of mitochondrial oxidative phosphorylation

Cell metabolism, 2017-10, Vol.26 (4), p.633-647.e7

2017

Volltextzugriff (PDF)

Trastuzumab subcutáneo: revisión de los datos clínicos y de preferencia

Revista de senología y patología mamaria, 2014-07, Vol.27 (3), p.131-137

2014

Volltextzugriff (PDF)

Abstract B109: AZD5363, a catalytic pan-Akt inhibitor, in Akt1 E17K mutation positive advanced solid tumors

Molecular cancer therapeutics, 2015-12, Vol.14 (12_Supplement_2), p.B109-B109

2015

Volltextzugriff (PDF)

Abstract C252: A phase 1, dose-escalation study of MLN0128, an investigational oral mammalian target of rapamycin complex 1/2 (mTORC1/2) catalytic inhibitor, in patients (pts) with advanced non-hematologic malignancies

Molecular cancer therapeutics, 2013-11, Vol.12 (11_Supplement), p.C252-C252

2013

Volltextzugriff (PDF)

Primary paraesophageal Ewing's sarcoma: an uncommon case report and literature review

OncoTargets and therapy, 2015, Vol.8, p.1053-1059

2015

Volltextzugriff (PDF)

Distinct mechanisms of resistance to fulvestrant treatment dictate level of ER independence and selective response to CDK inhibitors in metastatic breast cancer

Breast cancer research : BCR, 2021-02, Vol.23 (1), p.26-18, Article 26

2021

Volltextzugriff (PDF)

1 – 25 von 47

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(43)
Mit Volltextzugriff
(39)

Publikationsform

Sprache

Erscheinungsjahr

n.n

Thema

15 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 90 Tagen
(2)

Menü

Weitere Dienste

Einstellungen

A phase Ib/II study of xentuzumab, an IGF-neutralising antibody, combined with exemestane and everolimus in hormone receptor-positive, HER2-negative locally advanced/metastatic breast cancer

Aurora kinases in ovarian cancer

MYC and MCL1 Cooperatively Promote Chemotherapy-Resistant Breast Cancer Stem Cells via Regulation of Mitochondrial Oxidative Phosphorylation

Phase Ia/b Study of Giredestrant ± Palbociclib and ± Luteinizing Hormone-Releasing Hormone Agonists in Estrogen Receptor-Positive, HER2-Negative, Locally Advanced/Metastatic Breast Cancer

Molecular biology in breast cancer: Intrinsic subtypes and signaling pathways

Immunotherapies in ovarian cancer

A Phase I Open-Label Study to Identify a Dosing Regimen of the Pan-AKT Inhibitor AZD5363 for Evaluation in Solid Tumors and in PIK3CA -Mutated Breast and Gynecologic Cancers

Treatment of cervical cancer: the importance of a multidisciplinary team approach

ER + Breast Cancers Resistant to Prolonged Neoadjuvant Letrozole Exhibit an E2F4 Transcriptional Program Sensitive to CDK4/6 Inhibitors

Clinical implications of routine genomic mutation sequencing in PIK3CA/AKT1 and KRAS/NRAS/BRAF in metastatic breast cancer

Systemic treatment of newly diagnosed advanced epithelial ovarian cancer: From chemotherapy to precision medicine

EGF-Induced Acetylation of Heterogeneous Nuclear Ribonucleoproteins Is Dependent on KRAS Mutational Status in Colorectal Cancer Cells

Cell proliferation inhibitors and apoptosis promoters

Primary paraesophageal Ewing's sarcoma: an uncommon case report and literature review

GEICO1601-ROLANDO: a multicentric single arm Phase II clinical trial to evaluate the combination of olaparib and pegylated liposomal doxorubicin for platinum-resistant ovarian cancer

Endometriosis-associated ovarian carcinomas: insights into pathogenesis, diagnostics, and therapeutic targets-a narrative review

2022-RA-459-ESGO UPLIFT (ENGOT-ov67/GOG-3048) a registrational trial of Upifitamab Rilsodotin (XMT-1536; UpRi), a NaPi2b-directed antibody drug conjugate (ADC) in platinum-resistant ovarian cancer

Correction: ER + Breast Cancers Resistant to Prolonged Neoadjuvant Letrozole Exhibit an E2F4 Transcriptional Program Sensitive to CDK4/6 Inhibitors

MYC and MCL1 cooperatively promote chemotherapy-resistant breast cancer stem cells through regulation of mitochondrial oxidative phosphorylation

Trastuzumab subcutáneo: revisión de los datos clínicos y de preferencia

Abstract B109: AZD5363, a catalytic pan-Akt inhibitor, in Akt1 E17K mutation positive advanced solid tumors

Abstract C252: A phase 1, dose-escalation study of MLN0128, an investigational oral mammalian target of rapamycin complex 1/2 (mTORC1/2) catalytic inhibitor, in patients (pts) with advanced non-hematologic malignancies

Primary paraesophageal Ewing's sarcoma: an uncommon case report and literature review

Efficacy of niraparib by time of surgery and postoperative residual disease status: A post hoc analysis of patients in the PRIMA/ENGOT-OV26/GOG-3012 study

Distinct mechanisms of resistance to fulvestrant treatment dictate level of ER independence and selective response to CDK inhibitors in metastatic breast cancer

Suchergebnisse filtern